Senti Biosciences Holdings (SNTI) Preferred Stock Liabilities (2021 - 2024)
Senti Biosciences Holdings (SNTI) posted quarterly Preferred Stock Liabilities of $25.1 million for Q4 2024, down 85.39% quarter-over-quarter from $171.8 million in Q1 2022.
Senti Biosciences Holdings (SNTI) Preferred Stock Liabilities (2021 - 2024) Analysis & Trends
Senti Biosciences Holdings' Preferred Stock Liabilities history runs 3 years deep, the most recent figure standing at $25.1 million for Q4 2024.
- In Q4 2024, Preferred Stock Liabilities changed N/A year-over-year to $25.1 million; the TTM figure through Dec 2024 stood at $25.1 million (changed N/A YoY), while the FY2024 annual figure was $25.1 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q4 2024 stood at $25.1 million, down from $171.8 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $171.8 million in Q2 2021, with the low at $25.1 million in Q4 2024.
- The 3-year median for Preferred Stock Liabilities is $171.8 million (2021), against an average of $134.1 million.
- Peak annual rise in Preferred Stock Liabilities reached 86.86% in 2022, while the deepest fall reached 86.86% in 2022.
- Senti Biosciences Holdings' Preferred Stock Liabilities stood at $171.8 million in 2021, then changed by 0.0% to $171.8 million in 2022, then tumbled by 85.39% to $25.1 million in 2024.
- Business Quant data shows SNTI's Preferred Stock Liabilities at $25.1 million in Q4 2024, $171.8 million in Q1 2022, and $171.8 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Senti Biosciences Holdings | 12.06 Mn | 12.06 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 25.11 Mn |
| Mar 31, 2022 | 171.83 Mn |
| Dec 31, 2021 | 171.83 Mn |
| Sep 30, 2021 | 171.83 Mn |
| Jun 30, 2021 | 171.83 Mn |
| Mar 31, 2021 | 91.96 Mn |